nodes	percent_of_prediction	percent_of_DWPC	metapath
Naphazoline—Eye oedema—Pazopanib—kidney cancer	0.122	0.131	CcSEcCtD
Naphazoline—Punctate keratitis—Capecitabine—kidney cancer	0.0353	0.0379	CcSEcCtD
Naphazoline—NISCH—Vincristine—Vinblastine—kidney cancer	0.0319	0.554	CbGdCrCtD
Naphazoline—Keratitis—Erlotinib—kidney cancer	0.0288	0.0309	CcSEcCtD
Naphazoline—NISCH—Vinblastine—Vincristine—kidney cancer	0.0256	0.446	CbGdCrCtD
Naphazoline—Lacrimation increased—Sunitinib—kidney cancer	0.0175	0.0188	CcSEcCtD
Naphazoline—Keratitis—Paclitaxel—kidney cancer	0.0167	0.018	CcSEcCtD
Naphazoline—Redness—Paclitaxel—kidney cancer	0.0161	0.0173	CcSEcCtD
Naphazoline—Hyperglycaemia—Temsirolimus—kidney cancer	0.0147	0.0158	CcSEcCtD
Naphazoline—Keratitis—Capecitabine—kidney cancer	0.0137	0.0148	CcSEcCtD
Naphazoline—Eye disorder—Temsirolimus—kidney cancer	0.0122	0.0131	CcSEcCtD
Naphazoline—Lacrimation increased—Paclitaxel—kidney cancer	0.0118	0.0127	CcSEcCtD
Naphazoline—Eye disorder—Pazopanib—kidney cancer	0.0115	0.0124	CcSEcCtD
Naphazoline—Erythema—Temsirolimus—kidney cancer	0.0114	0.0122	CcSEcCtD
Naphazoline—Hyperglycaemia—Everolimus—kidney cancer	0.0109	0.0118	CcSEcCtD
Naphazoline—Erythema—Pazopanib—kidney cancer	0.0107	0.0115	CcSEcCtD
Naphazoline—Vision blurred—Pazopanib—kidney cancer	0.0101	0.0108	CcSEcCtD
Naphazoline—Hypertension—Temsirolimus—kidney cancer	0.00982	0.0105	CcSEcCtD
Naphazoline—Lacrimation—Doxorubicin—kidney cancer	0.00977	0.0105	CcSEcCtD
Naphazoline—Lacrimation increased—Capecitabine—kidney cancer	0.00967	0.0104	CcSEcCtD
Naphazoline—Hypertension—Pazopanib—kidney cancer	0.00925	0.00994	CcSEcCtD
Naphazoline—Hyperglycaemia—Sunitinib—kidney cancer	0.00915	0.00983	CcSEcCtD
Naphazoline—Eye disorder—Everolimus—kidney cancer	0.00908	0.00975	CcSEcCtD
Naphazoline—Keratitis—Doxorubicin—kidney cancer	0.00885	0.00951	CcSEcCtD
Naphazoline—Eye disorder—Erlotinib—kidney cancer	0.00876	0.00941	CcSEcCtD
Naphazoline—Eye pain—Paclitaxel—kidney cancer	0.00873	0.00938	CcSEcCtD
Naphazoline—Redness—Doxorubicin—kidney cancer	0.00851	0.00914	CcSEcCtD
Naphazoline—Erythema—Everolimus—kidney cancer	0.00846	0.00909	CcSEcCtD
Naphazoline—Hyperhidrosis—Pazopanib—kidney cancer	0.00845	0.00908	CcSEcCtD
Naphazoline—Somnolence—Temsirolimus—kidney cancer	0.00825	0.00886	CcSEcCtD
Naphazoline—Erythema—Erlotinib—kidney cancer	0.00816	0.00877	CcSEcCtD
Naphazoline—Vision blurred—Everolimus—kidney cancer	0.00797	0.00856	CcSEcCtD
Naphazoline—Somnolence—Pazopanib—kidney cancer	0.00777	0.00835	CcSEcCtD
Naphazoline—Terbinafine—PTGS1—kidney cancer	0.00765	0.656	CrCbGaD
Naphazoline—Eye disorder—Sunitinib—kidney cancer	0.00758	0.00815	CcSEcCtD
Naphazoline—Erythema—Sorafenib—kidney cancer	0.00734	0.00789	CcSEcCtD
Naphazoline—Hyperglycaemia—Gemcitabine—kidney cancer	0.00734	0.00788	CcSEcCtD
Naphazoline—Hypertension—Vinblastine—kidney cancer	0.00733	0.00788	CcSEcCtD
Naphazoline—Sweating—Vincristine—kidney cancer	0.00733	0.00788	CcSEcCtD
Naphazoline—Hypertension—Everolimus—kidney cancer	0.0073	0.00784	CcSEcCtD
Naphazoline—Eye pain—Capecitabine—kidney cancer	0.00716	0.0077	CcSEcCtD
Naphazoline—Discomfort—Vinblastine—kidney cancer	0.00714	0.00767	CcSEcCtD
Naphazoline—Discomfort—Everolimus—kidney cancer	0.00711	0.00764	CcSEcCtD
Naphazoline—Erythema—Sunitinib—kidney cancer	0.00706	0.00759	CcSEcCtD
Naphazoline—Sweating—Gemcitabine—kidney cancer	0.00695	0.00747	CcSEcCtD
Naphazoline—Erythema—Dactinomycin—kidney cancer	0.00669	0.00718	CcSEcCtD
Naphazoline—Hyperhidrosis—Everolimus—kidney cancer	0.00667	0.00717	CcSEcCtD
Naphazoline—Asthenia—Temsirolimus—kidney cancer	0.00666	0.00715	CcSEcCtD
Naphazoline—Hypertension—Sorafenib—kidney cancer	0.00634	0.00681	CcSEcCtD
Naphazoline—Asthenia—Pazopanib—kidney cancer	0.00627	0.00674	CcSEcCtD
Naphazoline—Lacrimation increased—Doxorubicin—kidney cancer	0.00623	0.00669	CcSEcCtD
Naphazoline—Hyperglycaemia—Paclitaxel—kidney cancer	0.00614	0.0066	CcSEcCtD
Naphazoline—Somnolence—Everolimus—kidney cancer	0.00614	0.00659	CcSEcCtD
Naphazoline—Dizziness—Temsirolimus—kidney cancer	0.00614	0.00659	CcSEcCtD
Naphazoline—Hypertension—Sunitinib—kidney cancer	0.0061	0.00655	CcSEcCtD
Naphazoline—Headache—Temsirolimus—kidney cancer	0.00581	0.00625	CcSEcCtD
Naphazoline—Dizziness—Pazopanib—kidney cancer	0.00578	0.00621	CcSEcCtD
Naphazoline—Erythema—Gemcitabine—kidney cancer	0.00567	0.00609	CcSEcCtD
Naphazoline—Discomfort—Dactinomycin—kidney cancer	0.00563	0.00604	CcSEcCtD
Naphazoline—Nausea—Temsirolimus—kidney cancer	0.00551	0.00592	CcSEcCtD
Naphazoline—Headache—Pazopanib—kidney cancer	0.00548	0.00588	CcSEcCtD
Naphazoline—Nausea—Pazopanib—kidney cancer	0.00519	0.00558	CcSEcCtD
Naphazoline—Hypertension—Vincristine—kidney cancer	0.00516	0.00554	CcSEcCtD
Naphazoline—Eye disorder—Paclitaxel—kidney cancer	0.00509	0.00547	CcSEcCtD
Naphazoline—Hyperglycaemia—Capecitabine—kidney cancer	0.00504	0.00542	CcSEcCtD
Naphazoline—Asthenia—Vinblastine—kidney cancer	0.00497	0.00534	CcSEcCtD
Naphazoline—Asthenia—Everolimus—kidney cancer	0.00495	0.00532	CcSEcCtD
Naphazoline—Hypertension—Gemcitabine—kidney cancer	0.00489	0.00526	CcSEcCtD
Naphazoline—Asthenia—Erlotinib—kidney cancer	0.00478	0.00513	CcSEcCtD
Naphazoline—Discomfort—Gemcitabine—kidney cancer	0.00477	0.00512	CcSEcCtD
Naphazoline—Erythema—Paclitaxel—kidney cancer	0.00475	0.0051	CcSEcCtD
Naphazoline—Hyperhidrosis—Vincristine—kidney cancer	0.00471	0.00506	CcSEcCtD
Naphazoline—Tension—Paclitaxel—kidney cancer	0.00466	0.005	CcSEcCtD
Naphazoline—Eye pain—Doxorubicin—kidney cancer	0.00462	0.00496	CcSEcCtD
Naphazoline—Nervousness—Paclitaxel—kidney cancer	0.00461	0.00495	CcSEcCtD
Naphazoline—Dizziness—Vinblastine—kidney cancer	0.00458	0.00492	CcSEcCtD
Naphazoline—Dizziness—Everolimus—kidney cancer	0.00456	0.0049	CcSEcCtD
Naphazoline—Vision blurred—Paclitaxel—kidney cancer	0.00447	0.00481	CcSEcCtD
Naphazoline—Hyperhidrosis—Gemcitabine—kidney cancer	0.00447	0.0048	CcSEcCtD
Naphazoline—Dizziness—Erlotinib—kidney cancer	0.0044	0.00473	CcSEcCtD
Naphazoline—Headache—Vinblastine—kidney cancer	0.00434	0.00466	CcSEcCtD
Naphazoline—Headache—Everolimus—kidney cancer	0.00432	0.00465	CcSEcCtD
Naphazoline—Asthenia—Sorafenib—kidney cancer	0.0043	0.00462	CcSEcCtD
Naphazoline—Eye disorder—Capecitabine—kidney cancer	0.00418	0.00449	CcSEcCtD
Naphazoline—Headache—Erlotinib—kidney cancer	0.00417	0.00448	CcSEcCtD
Naphazoline—Asthenia—Sunitinib—kidney cancer	0.00414	0.00444	CcSEcCtD
Naphazoline—Nausea—Vinblastine—kidney cancer	0.00412	0.00442	CcSEcCtD
Naphazoline—Somnolence—Gemcitabine—kidney cancer	0.00411	0.00442	CcSEcCtD
Naphazoline—Nausea—Everolimus—kidney cancer	0.0041	0.0044	CcSEcCtD
Naphazoline—Hypertension—Paclitaxel—kidney cancer	0.0041	0.0044	CcSEcCtD
Naphazoline—Discomfort—Paclitaxel—kidney cancer	0.00399	0.00429	CcSEcCtD
Naphazoline—Dizziness—Sorafenib—kidney cancer	0.00396	0.00426	CcSEcCtD
Naphazoline—Nausea—Erlotinib—kidney cancer	0.00396	0.00425	CcSEcCtD
Naphazoline—Asthenia—Dactinomycin—kidney cancer	0.00392	0.00421	CcSEcCtD
Naphazoline—Erythema—Capecitabine—kidney cancer	0.00389	0.00418	CcSEcCtD
Naphazoline—Dizziness—Sunitinib—kidney cancer	0.00381	0.0041	CcSEcCtD
Naphazoline—Headache—Sorafenib—kidney cancer	0.00375	0.00403	CcSEcCtD
Naphazoline—Hyperhidrosis—Paclitaxel—kidney cancer	0.00374	0.00402	CcSEcCtD
Naphazoline—Vision blurred—Capecitabine—kidney cancer	0.00367	0.00394	CcSEcCtD
Naphazoline—Headache—Sunitinib—kidney cancer	0.00361	0.00388	CcSEcCtD
Naphazoline—Nausea—Sorafenib—kidney cancer	0.00356	0.00382	CcSEcCtD
Naphazoline—Asthenia—Vincristine—kidney cancer	0.0035	0.00376	CcSEcCtD
Naphazoline—Somnolence—Paclitaxel—kidney cancer	0.00344	0.0037	CcSEcCtD
Naphazoline—Nausea—Sunitinib—kidney cancer	0.00342	0.00368	CcSEcCtD
Naphazoline—Hypertension—Capecitabine—kidney cancer	0.00336	0.00361	CcSEcCtD
Naphazoline—Asthenia—Gemcitabine—kidney cancer	0.00332	0.00357	CcSEcCtD
Naphazoline—Discomfort—Capecitabine—kidney cancer	0.00328	0.00352	CcSEcCtD
Naphazoline—Hyperglycaemia—Doxorubicin—kidney cancer	0.00325	0.00349	CcSEcCtD
Naphazoline—Nausea—Dactinomycin—kidney cancer	0.00324	0.00348	CcSEcCtD
Naphazoline—Dizziness—Vincristine—kidney cancer	0.00322	0.00346	CcSEcCtD
Naphazoline—Drowsiness—Doxorubicin—kidney cancer	0.00321	0.00345	CcSEcCtD
Naphazoline—Sweating—Doxorubicin—kidney cancer	0.00308	0.00331	CcSEcCtD
Naphazoline—Hyperhidrosis—Capecitabine—kidney cancer	0.00307	0.0033	CcSEcCtD
Naphazoline—Headache—Vincristine—kidney cancer	0.00306	0.00328	CcSEcCtD
Naphazoline—Headache—Gemcitabine—kidney cancer	0.0029	0.00311	CcSEcCtD
Naphazoline—Nausea—Vincristine—kidney cancer	0.0029	0.00311	CcSEcCtD
Naphazoline—Asthenia—Paclitaxel—kidney cancer	0.00278	0.00299	CcSEcCtD
Naphazoline—Nausea—Gemcitabine—kidney cancer	0.00275	0.00295	CcSEcCtD
Naphazoline—Eye disorder—Doxorubicin—kidney cancer	0.0027	0.0029	CcSEcCtD
Naphazoline—Propranolol—CYP1A1—kidney cancer	0.00262	0.225	CrCbGaD
Naphazoline—Dizziness—Paclitaxel—kidney cancer	0.00256	0.00275	CcSEcCtD
Naphazoline—Erythema—Doxorubicin—kidney cancer	0.00251	0.0027	CcSEcCtD
Naphazoline—Tension—Doxorubicin—kidney cancer	0.00246	0.00265	CcSEcCtD
Naphazoline—Nervousness—Doxorubicin—kidney cancer	0.00244	0.00262	CcSEcCtD
Naphazoline—Headache—Paclitaxel—kidney cancer	0.00243	0.00261	CcSEcCtD
Naphazoline—Vision blurred—Doxorubicin—kidney cancer	0.00237	0.00254	CcSEcCtD
Naphazoline—Nausea—Paclitaxel—kidney cancer	0.0023	0.00247	CcSEcCtD
Naphazoline—Asthenia—Capecitabine—kidney cancer	0.00228	0.00245	CcSEcCtD
Naphazoline—Hypertension—Doxorubicin—kidney cancer	0.00217	0.00233	CcSEcCtD
Naphazoline—Discomfort—Doxorubicin—kidney cancer	0.00211	0.00227	CcSEcCtD
Naphazoline—Dizziness—Capecitabine—kidney cancer	0.0021	0.00226	CcSEcCtD
Naphazoline—Headache—Capecitabine—kidney cancer	0.00199	0.00214	CcSEcCtD
Naphazoline—Hyperhidrosis—Doxorubicin—kidney cancer	0.00198	0.00213	CcSEcCtD
Naphazoline—Nausea—Capecitabine—kidney cancer	0.00189	0.00203	CcSEcCtD
Naphazoline—Somnolence—Doxorubicin—kidney cancer	0.00182	0.00196	CcSEcCtD
Naphazoline—Asthenia—Doxorubicin—kidney cancer	0.00147	0.00158	CcSEcCtD
Naphazoline—Propranolol—ABCB1—kidney cancer	0.00139	0.12	CrCbGaD
Naphazoline—Dizziness—Doxorubicin—kidney cancer	0.00135	0.00146	CcSEcCtD
Naphazoline—Headache—Doxorubicin—kidney cancer	0.00128	0.00138	CcSEcCtD
Naphazoline—Nausea—Doxorubicin—kidney cancer	0.00122	0.00131	CcSEcCtD
